Investigating how a protein in psoriasis may lead to diabetes
Role of IFN kappa in psoriasis-mediated diabetes development
['FUNDING_OTHER'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-11078495
This study is looking at how psoriasis might increase the risk of developing type 2 diabetes by exploring a protein called interferon kappa, which is higher in people with psoriasis, and how it affects inflammation and metabolism, with the goal of finding new treatment options for those dealing with both conditions.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-11078495 on ClinicalTrials.gov |
What this research studies
This research explores the connection between psoriasis, a chronic skin condition, and the increased risk of developing type 2 diabetes. It focuses on the role of interferon kappa (IFNκ), a protein that is elevated in psoriasis, and how it may contribute to inflammation and metabolic changes that lead to diabetes. The study aims to understand the molecular mechanisms involved, particularly how certain signaling pathways affect the expression of IFNκ in skin cells and its impact on inflammatory cells in the body. By uncovering these mechanisms, the research hopes to provide insights into potential therapeutic targets for patients with both psoriasis and diabetes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with psoriasis who are at risk of developing type 2 diabetes.
Not a fit: Patients without psoriasis or those who do not have a risk of developing diabetes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that help manage or prevent diabetes in patients with psoriasis.
How similar studies have performed: Previous research has shown that understanding the inflammatory pathways in psoriasis can lead to significant advancements in treatment, suggesting that this approach may yield valuable insights.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WOLF-FORTUNE, SONYA J — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: WOLF-FORTUNE, SONYA J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Adult-Onset Diabetes Mellitus